Alpha-2 Adrenergic Receptors and Attention-Deficit/Hyperactivity Disorder
- 23 July 2010
- journal article
- review article
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 12 (5) , 366-373
Abstract
Pharmacologic management of attention-deficit/hyperactivity disorder (ADHD) has expanded beyond stimulant medications to include α-2 adrenergic agonists. These agents exert their actions through presynaptic stimulation and likely involve facilitation of dopamine and noradrenaline neurotransmission, both of which are thought to play critical roles in the pathophysiology of ADHD. Furthermore, frontostriatal dysfunction giving rise to neuropsychological weaknesses has been well-established in patients with ADHD and may explain how α-2 agents exert their beneficial effects. In the following review, we consider relevant neurobiological underpinnings of ADHD with respect to why α-2 agents may be effective in treating this condition. We also review new formulations of α-2 agonists, emerging data on their use in ADHD, and implications for clinical practice. Integrating knowledge of pathophysiologic mechanisms and mechanisms of drug action may inform our medication choices and facilitate treatment of ADHD and related disorders.Keywords
This publication has 76 references indexed in Scilit:
- Candidate gene studies of ADHD: a meta-analytic reviewHuman Genetics, 2009
- Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2009
- Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity DisorderPediatrics, 2008
- Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 yearsClinical Therapeutics, 2007
- Prevalence, Recognition, and Treatment of Attention-Deficit/Hyperactivity Disorder in a National Sample of US ChildrenArchives of Pediatrics & Adolescent Medicine, 2007
- α2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animalsLearning & Memory, 2006
- Clonidine, but not Guanfacine, Impairs Choice Reaction Time Performance in Young Healthy VolunteersNeuropsychopharmacology, 1999
- Delayed-response deficit induced by local injection of the α2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeysBehavioral and Neural Biology, 1994
- Clonidine: A new antihypertensive agentThe American Journal of Cardiology, 1971